Journal Mobile Options
Table of Contents
Vol. 136, No. 3, 2005
Issue release date: March 2005
Section title: Original Paper
Int Arch Allergy Immunol 2005;136:281–286
(DOI:10.1159/000083955)

Quality of Life during Pollen Season in Patients with Seasonal Allergic Rhinitis with or without Asthma

Laforest L. · Bousquet J. · Pietri G. · Sazonov Kocevar V. · Yin D. · Pacheco Y. · van Ganse E.
aPharmacoepidemiology Unit, EA3091 CHU Lyon-Sud, Pierre-Bénite, bDepartment of Respiratory Medicine, CHU, Montpellier, France; cRutgers University, Piscataway, N.J., dMerck & Co., Inc., Whitehouse Station, N.J., USA; eDepartment ofRespiratory Medicine, EA3091 CHU Lyon-Sud, Pierre-Bénite, France

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/16/2004
Accepted: 11/8/2004
Published online: 3/16/2005

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA

Abstract

Objectives: We studied the evolution of generic and rhinoconjunctivitis-specific quality of life (QOL) during pollen season in patients with isolated seasonal allergic rhinitis (SAR) and those with asthma and concomitant SAR (AS+SAR). Generic QOL between groups was also compared at pollen peak. Methods: A prospective cohort study was conducted in Southern France in 2002. Outpatients aged 18–60, regularly visiting respiratory physicians for SAR, were recruited before the grass (grass cohort) or ragweed pollination period (ragweed cohort). Before the pollination period (baseline) and at peak pollination, patients completed French versions of the Mini Rhinoconjuctivitis Quality of Life Questionnaire (Mini-RQLQ) and physical and mental Short Form-12 (SF-12) scores (PCS and MCS) to determine rhinoconjunctivitis and generic QOL. Results: Totals of 83 and 52 patients were included in the SAR and AS+SAR groups, respectively (mean age = 35.4; 56.4% females). Mini-RQLQ scores indicated slightly worse QOL in the A+SAR group at inclusion, which significantly deteriorated at the time of pollen peak, both in the SAR (p < 0.0001) and AS+SAR groups (p = 0.003). In univariate analysis, significantly higher SF-12 PCS (meaning better QOL) were observed at pollen peak in the SAR compared with the AS+SAR group (p = 0.0008), while the difference for SF-12 MCS was more limited (p = 0.05). Results were confirmed in multivariable analyses adjusting for gender, allergy medication use at pollen peak, cohort of inclusion (grass/ragweed) and comorbid conditions. Conclusions: Significant deterioration in rhinoconjunctivitis-specific QOL was observed through the pollination period in patients with SAR and AS+SAR. At pollen peak, AS+SAR patients experienced significantly worse physical functioning than patients with SAR alone.


  

Author Contacts

Correspondence to: Dr. Eric Van Ganse
Unité de Pharmacoépidémiologie
Ste Eugénie (bâtiment 5F), Centre Hospitalier Lyon-Sud (CHLS)
FR–69495 Pierre-Bénite Cedex (France)
Tel. +33 472 66 64 38, Fax +33 472 66 64 44, E-Mail eric.van-ganse@chu-lyon.fr

  

Article Information

Received: August 16, 2004
Accepted after revision: November 8, 2004
Published online: February 17, 2005
Number of Print Pages : 6
Number of Figures : 0, Number of Tables : 3, Number of References : 17

  

Publication Details

International Archives of Allergy and Immunology

Vol. 136, No. 3, Year 2005 (Cover Date: March 2005)

Journal Editor: Valenta, R. (Vienna)
ISSN: 1018–2438 (print), 1423–0097 (Online)

For additional information: http://www.karger.com/iaa


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/16/2004
Accepted: 11/8/2004
Published online: 3/16/2005

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 3

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.